

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014, as it forms part of UK Domestic Law by virtue of the European Union (Withdrawal) Act 2018. Upon the publication of this announcement, this inside information is now considered to be in the public domain.

29 February 2024

**SEED Innovations Limited**  
("SEED" or the "Company")

**Continuation of Existing Share Buy-Back Programme**

SEED Innovations Ltd, the AIM-quoted investment company with a portfolio of disruptive, high-growth life sciences and technology companies, is pleased to announce that it has extended its existing share repurchase programme (see RNS dated 19 September 2023) of Ordinary Shares (the "Programme") for up to a maximum of 21,500,000 shares and £850,000 for a further three months from the expiry of the original programme term to 30 May 2024. To date, 9,927,000 shares have been bought for c.£288,988.45.

Save for the extension of its term, the programme will continue to be run on the basis set out in the Company's announcement of 19 September 2023.

Any purchase of Ordinary Shares made in relation to this announcement will be carried out on the open market during the period commencing 1 March 2024 and ending not later than 30 May 2024. The Programme will be funded from the Company's existing cash resources.

Share purchases will take place in open market transactions and may be made from time to time depending on market conditions, share price, trading volume and other factors. Shard Capital Partners LLP is the Company's broker in relation to the Programme. The shares purchased by the Company will be held in treasury pending cancellation or re-issue.

The Programme will be conducted within the safe harbour parameters of the Market Abuse Regulation 596/2014/EU and the Commission Delegated Regulation 2016/1052/EU (each as incorporated into UK domestic law by the European Union (Withdrawal) Act 2018, including where relevant pursuant to the Market Abuse (Amendment) (EU Exit) Regulations 2019). Details of all purchases made pursuant to the Programme will be announced via RNS and published on the Company's website as required by the Market Abuse Regulations.

**-Ends-**

For further information on the Company please visit: [www.seedinnovations.co](http://www.seedinnovations.co) or contact:

Ed McDermott Lance de Jersey	SEED Innovations Ltd	E: <a href="mailto:info@seedinnovations.co">info@seedinnovations.co</a>
James Biddle Roland Cornish	Beaumont Cornish Limited, Nomad	T: (0)20 7628 3396
Isabella Pierre Damon Heath	Shard Capital Partners LLP Broker	T: (0)20 7186 9927
Ana Ribeiro Isabelle Morris	St Brides Partners Ltd, Financial PR	E: <a href="mailto:seed@stbridespartners.co.uk">seed@stbridespartners.co.uk</a>

**Notes**

**SEED Innovations Ltd**

SEED Innovations Ltd is an AIM-quoted investment company providing shareholders with exposure to disruptive, high-growth, life sciences and technology companies. Its strategy is to identify early-stage opportunities that have an upcoming investment catalyst, and more mature investments that offer liquidity in the near term. To this end, it currently has eight active investments with a balance of liquid, pre-liquidity, and longer-term opportunities and is positioned to move quickly

on other investment opportunities.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

POSEAPANAEXLEEA